Alder BioPharma
Lundbeck appoints Tarek Samad as EVP, Head of Research & Development
Samad previously held senior research leadership positions at Immunitas Therapeutics, Sanofi and Pfizer
Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment
The rare neurodegenerative disorder has no cure and no approved treatments
Lundbeck drops Parkinson’s drug acquired in €905m deal
Disappointment after drug failed in a mid-stage clinical trial
Lundbeck gets US approval for migraine drug at heart of Alder takeover
US regulator clears CGRP inhibitor under Vyepti trade name
Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug
Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’
Lundbeck and Otsuka start phase III for Rexulti in bipolar
Drug is also in phase II trial to treat PTSD patients
Teva poaches Lundbeck’s Schultz as new CEO
Shares in Lundbeck fall as two senior posts become vacant
Lundbeck partners with 23andMe on first-of-its-kind study
Psychiatry collaboration will combine data from genetics, cognitive tests and online surveys
Lundbeck partners with IBM Watson on drug research
The deal will also see it set up a new real world evidence platform